原发与转移性肝肿瘤中99mTc-MAA SPECT/CT与90Y PET/CT的剂量学比较
结果显示非肿瘤肝剂量在3组均<50 Gy且相关性高,99mTc-MAA SPECT/CT对HCC肿瘤剂量的预测优于转移瘤,与微球类型无关。
要点
- 99mTc-MAA SPECT/CT可较可靠预测非肿瘤肝剂量,无论微球类型。
- 对HCC肿瘤剂量预测较可靠,但存在个体差异。
- 对肝转移瘤肿瘤剂量预测一致性较低(CCC 0.52)。
核心结论
- 99mTc-MAA SPECT/CT对HCC和转移瘤的非肿瘤肝剂量预测均较可靠,与微球类型无关。
- 对HCC肿瘤剂量预测也较可靠,与微球类型无关,但存在个体差异。
研究设计与样本
- 比较99mTc-MAA SPECT/CT与90Y PET/CT测得的肿瘤肝(Dm)和非肿瘤肝(DmNTL)平均吸收剂量。
主要发现
- 3组非肿瘤肝剂量DmNTL均<50 Gy,全人群强相关,转移组略低于HCC-SIR和HCC-Thera(CCC分别为0.8、0.94、0.96)。
- 肿瘤肝Dm在HCC中高于转移瘤(159 ± 117 Gy vs 63 ± 31 Gy)。
- 99mTc-MAA SPECT/CT预测HCC的Dm优于转移瘤,树脂与玻璃微球一致性相似(CCC HCC-SIR 0.82、HCC-Thera 0.82、Metastases-SIR 0.52)。
关键数值与推荐
- 非肿瘤肝剂量DmNTL在3组均<50 Gy。
- CCC:HCC-SIR 0.94、HCC-Thera 0.96、Metastases-SIR 0.8(非肿瘤肝)。
- CCC:HCC-SIR 0.82、HCC-Thera 0.82、Metastases-SIR 0.52(肿瘤肝)。
临床怎么用
- 可用99mTc-MAA SPECT/CT术前预测非肿瘤肝剂量以评估安全性。
- 对HCC可较可靠预测肿瘤剂量,但需注意个体差异。
- 对肝转移瘤肿瘤剂量预测一致性较低,解读需谨慎。
局限性
- 回顾性研究设计。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: The aim of this study is to determine whether 99mTc-MAA SPECT/CT-based dosimetry could predict the actual absorbed dose in hepatocellular carcinoma (HCC) or liver metastases, treated by glass or resin microspheres. MATERIAL AND METHODS: Fifty-seven patients who underwent selective internal radiation therapy (SIRT) were retrospectively included in the study, for a total of 59 treatments. Nineteen HCC were treated by resin microspheres (HCC-SIR), 20 HCC with glass microspheres (HCC-Thera), and 20 liver metastases with resin microspheres (Metastases-SIR). The mean absorbed doses in tumoral liver (Dm) and non-tumoral liver (DmNTL) were determined on the 99mTc-MAA SPECT/CT and the 90Y PET/CT, and compared with each other. RESULTS: DmNTL was < 50 Gy in the 3 groups, with a strong correlation in all population, albeit slightly lower in Metastases-SIR than HCC-SIR and HCC-Thera (CCC 0.8, 0.94 and 0.96, respectively). In tumoral liver, Dm was higher in HCC than metastases (159 ± 117 Gy versus 63 ± 31 Gy). 99mTc-MAA SPECT/CT proved to be a better indicator of Dm in HCC compared with metastases, with similar 99mTc-MAA-90Y concordance in resin and glass microspheres (CCC HCC-SIR 0.82, CCC HCC-Thera 0.82, and CCC Metastases-SIR 0.52). CONCLUSION: 99mTc-MAA SPECT/CT is a reasonably reliable tool for predicting the dose to the non-tumoral liver in both HCC and metastases, regardless of the type of microspheres. It is also fairly reliable for predicting the tumor dose in HCC, again regardless of the type of spheres, although individual variations are observed.
引用
- Jadoul A, Bernard C, Lovinfosse P, et al. Comparative dosimetry between 99mTc-MAA SPECT/CT and 90Y PET/CT in primary and metastatic liver tumors. Eur J Nucl Med Mol Imaging. 2019. PMID: 31388721. doi:10.1007/s00259-019-04465-7
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。